Vancouver, BC – TheNewswire - April 16, 2025 – GABO Mining Ltd. (TSXV: GAB | OTCQB: MLLOF | Frankfurt: MRDN) (the “Company” or “GABO”) is pleased to announce that a wholly owned subsidiary of the Company (Medallion Research USA, Inc.), has entered into a lease agreement dated April 14, 2025 with C Bar B Properties Corporation (the “Vendor”), pursuant to which the Company has been granted a four year lease, with exclusive option to purchase, two advanced-stage uranium exploration projects located in Utah an ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of RIET, HOMZ, IRET, ALL HOLDINGS IN THE IREIT+HOYA PORTFOLIOS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Hoya Capital Research & Index Innovations (“Hoya Capital”) is an affiliate of Hoya Capi ...

Contributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy veteran who enjoys dividend investing in quality blue-chip stocks, BDC's, and REITs. I am a buy-and-hold investor who prefers quality over quantity and plans to supplement his retirement income ...

LAUSANNE, Switzerland, April 1, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET. A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 da ...

However, several companies offer higher-yielding payouts for those seeking a bit more dividend income. Here are four top dividend stocks yielding around 4% these days that you can confidently buy for dividend income this April. Agree Realty Agree Realty (ADC 1.16%) has a 4% dividend yield. The real estate investment trust (REIT) focuses solely on owning single-tenant net lease and ground lease retail properties. Those lease structures provide very stable cash flow. Meanwhile, the REIT pays very close attent ...

Agree Realty Corporation is a publicly traded real estate investment trust that is RETHINKING RETAIL through the acquisition and development of properties net leased to industry-leading, omni-channel retail tenants. As of December 31, 2024, the Company owned and operated a portfolio of 2,370 properties, located in all 50 states and containing approximately 48.8 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC". Forward-Look ...

Core Viewpoint - Agree Realty (NYSE: ADC) has experienced a nearly 9% increase year-to-date on a total return basis, contrasting with the broader downturn affecting REITs due to a significantly narrower outlook for Federal Reserve rate cuts in 2025 and rising long-term US yields [1] Group 1 - The equity market serves as a powerful mechanism where daily price fluctuations can lead to substantial wealth creation or destruction over the long term [1] - Pacifica Yield focuses on long-term wealth creation by targeting undervalued yet high-growth companies, high-dividend stocks, REITs, and green energy firms [1]

Core Insights - ADC Therapeutics reported significant progress in clinical trials for ZYNLONTA, with a 94% overall response rate (ORR) and a 72% complete response (CR) rate in the LOTIS-7 Phase 1b trial [1][5] - The company completed enrollment in the LOTIS-5 Phase 3 trial, with data updates expected in late 2025 [1][5] - Financial results for Q4 and full year 2024 showed a net product revenue of $16.4 million for Q4 and $69.3 million for the full year, indicating a slight increase compared to 2023 [8][22] Operational Updates - The LOTIS-7 trial demonstrated promising initial data, with 94% ORR and 72% CR in patients with relapsed or refractory non-Hodgkin lymphoma [5] - Enrollment for the LOTIS-5 trial was completed in December 2024, with data updates anticipated once progression-free survival (PFS) events are reached [5] - The company is also advancing its early research solid tumor program to the IND-enabling stage [2] Financial Performance - Q4 2024 net product revenues were $16.4 million, compared to $16.6 million in Q4 2023, while full-year revenues increased from $69.1 million in 2023 to $69.3 million in 2024 [8][22] - Research and development expenses decreased to $27.1 million for Q4 2024 from $30.3 million in Q4 2023, and full-year expenses dropped from $127.1 million to $109.6 million [8][22] - The net loss for Q4 2024 was $30.7 million, a significant reduction from $85.0 million in Q4 2023, and the full-year net loss decreased from $240.1 million to $157.8 million [8][22] Cash Position - As of December 31, 2024, the company had $250.9 million in cash and cash equivalents, down from $278.6 million in 2023, providing a runway expected to fund operations into the second half of 2026 [1][8]

Group 1 - ADC Therapeutics is positioned in the large B-cell lymphoma market with its antibody-drug conjugate [1] - The company has previously shown optimism in its market positioning, leading to a rally in stock price [1] - The author has a background in biochemistry and experience in analyzing clinical trials and biotech companies, emphasizing the importance of understanding the science behind investments [1]

Core Viewpoint - Innovent Biologics has initiated the first participant dosing in a Phase 3 clinical trial (HeriCare-Ovarian01) for IBI354, targeting platinum-resistant ovarian cancer with HER2 expression, addressing an urgent medical need in this patient population [1][2][8]. Company Overview - Innovent Biologics is a biopharmaceutical company focused on developing high-quality medicines for various diseases, including oncology, cardiovascular, and autoimmune conditions [1][13]. - The company has launched 15 products and has multiple assets in various stages of clinical trials, indicating a robust pipeline and commitment to innovation [13]. Clinical Trial Details - The HeriCare-Ovarian01 trial is the first Phase 3 study in China for platinum-resistant ovarian cancer with HER2 expression, evaluating the safety and efficacy of IBI354 against standard chemotherapy [2][5]. - The primary endpoints of the trial include progression-free survival (PFS) and overall survival (OS) [2]. Previous Study Results - In a prior Phase 1/2 study, IBI354 demonstrated a 40.2% overall objective response rate (ORR) and an 81.6% disease control rate (DCR) among participants with platinum-resistant ovarian cancer [7]. - Notably, the ORR reached 52.5% and DCR 90.0% in patients treated with a 12 mg/kg dose [7]. Safety Profile - IBI354 has shown an excellent safety profile, with a low incidence of treatment-related adverse events (TRAEs) and no dose-limiting toxicities reported up to an 18 mg/kg dose [7][4]. - The most common TRAEs included nausea and decreased white blood cell count, with a very low incidence of interstitial lung disease [7]. HER2 Targeting - Approximately 38% of ovarian cancer patients express HER2, and there are currently no approved anti-HER2 treatments for this condition in China, highlighting the potential market opportunity for IBI354 [9][10]. - IBI354 is an innovative HER2-targeted antibody-drug conjugate developed using a proprietary platform, showcasing promising safety and efficacy signals [10][11]. Future Development - Innovent plans to expand the development of IBI354 to multiple solid tumor indications beyond ovarian cancer, indicating a strategic focus on broadening its therapeutic applications [12].